Poster Session C - Monday Afternoon
Category: IBD
Abdul S. Mohammed, MD
Cleveland Clinic
Orlando, FL
Factors | Ustekinumab | Vedolizumab | Odds ratio (95% confidence interval), P value |
Age | |||
Adults (18-65y) | 160 (84%) | 560 (80%) | 1.33 (0.86-2.05), 0.19 |
Seniors ( >65y) | 30 (16%) | 140 (21%) | 0.75 (0.48-1.15), 0.19 |
Race | |||
White | 170 (89%) | 630 (90%) | 0.94 (0.55-1.59), 0.83 |
Non-white | 20 (11%) | 70 (11%) | 1.05 (0.62-1.78), 0.83 |
Gender | |||
Female | 110 (58%) | 330 (47%) | 1.54 (1.11-2.13), 0.008 |
Male | 80 (42%) | 370 (53%) | 0.64 (0.46-0.89), 0.008 |
Clinical characteristics | |||
Tobacco user (current and former) | 178 (94%) | 660 (94%) | 0.65 (0.36-1.1), 0.17 |
Clostridium difficile infection | 40 (21%) | 140 (20%) | 1.06 (0.71-1.58), 0.74 |
Neoplasm of colon | 60 (32%) | 240 (34%) | 0.88 (0.62-1.24), 0.48 |